Risky Business: Should the FDA Pay Attention to Pharmaceutical Prices?

Authors

David A. Hyman
William E. Kovacic, George Washington University Law SchoolFollow

Document Type

Article

Publication Date

2017

Status

Accepted

Abstract

People are angry about drug prices. What role, if any, should the FDA play in addressing this issue? Historically, the FDA’s answer has been “not our problem.” As the quality and safety agency, the FDA has repeatedly refused to get involved in drug pricing matters, even when its actions (and inactions) have contributed to the problem. We examine the circumstances under which the FDA should pay attention to pharmaceutical prices, and discuss the implications of it doing so.

GW Paper Series

GWU Law School Public Law Research Paper No. 2017-37; GWU Legal Studies Research Paper No. 2017-37

SSRN Link

https://ssrn.com/abstract=2970683

Recommended Citation

Hyman, David A. and Kovacic, William E., Risky Business: Should the FDA Pay Attention to Pharmaceutical Prices? (May 18, 2017). GWU Law School Public Law Research Paper No. 2017-37; GWU Legal Studies Research Paper No. 2017-37. Available at SSRN: https://ssrn.com/abstract=2970683